Table 2.
Serum levels of biologics in patients with and without ADAbs.
| Authors | Disease | Study design (number of patients assessed) | Biologic agent, sampling time and other specifications | Serum concentration of biologic agent (µg/mL)a | p value | |
|---|---|---|---|---|---|---|
| Patients with ADAbs | Patients without ADAbs | |||||
| Imaeda and colleagues35 | CD | Prospective cohort study (58) | IFX: trough | 0.2 | 3.4 | p < 0.01 |
| Levesque and colleagues36 | CD | Prospective cohort study (327) | IFX: 0 weeks IFX: 8 weeks |
1.5 1.6 |
6.4 7.4 |
– – |
| Vermeire and colleagues37 | CD | Prospective cohort study (174) | IFX: 4 weeks ADAbs conc. <8 µg/mL ADAbs conc. ⩾8 and <20 µg/mL ADAbs conc. ⩾20 µg/mL |
12.3 7.2 6.1 |
10.1 10.1 10.1 |
– – – |
| Stein and colleagues28 (CA) | CD | Prospective cohort study (69) | IFX: 26 weeks IFX: 52 weeks |
0.9 2.5 |
7.6 9.5 |
– – |
| Ainsworth and colleagues38 | CD | Retrospective cohort study (33) | IFX: 8 weeks Maintained responders Secondary non-responders Primary non-responders |
2.9 0.0 30.0 |
NR NR NR |
– – – |
| Hämäläinen and colleagues46 | CD or UC cohort | Prospective cohort study (28) | IFX: trough Non-responders Responders |
<0.1 >2.2 |
NR NR |
– – |
| Pallagi-Kunstár and colleagues39 | CD or UC cohort | Prospective cohort study (67) | IFX: trough | 2.7 | 3.9 | p = 0.015 |
| Paul and colleagues40 | CD or UC cohort | Prospective cohort study (103) | IFX: trough IFX monotherapy IFX plus immunosuppressants |
2.4 2.1 |
NR NR |
– – |
| Rivera and colleagues29 (CA) | CD or UC cohort | Prospective cohort study (69) | IFX: trough | 1.8 | 9.0 | p < 0.001 |
| Ungar and colleagues41 | CD or UC cohort | Prospective cohort study (125) | IFX: trough Responders Non-responders |
4.6 0.7 |
– – |
– – |
| Zitomersky and colleagues42 | CD or UC cohort | Prospective cohort study (134) | IFX: trough | 1.0 | 12.2 | p < 0.0001 |
| Vande Casteele and colleagues47 | CD or UC cohort | Retrospective cohort study (90) | IFX: 6 weeks | 5 | 27 | p = 0.003 |
| Frederiksen and colleagues30 (CA) | CD or UC cohort | Retrospective cohort study (189) | IFX: trough | 0.0 | 1.8 | p = 0.002 |
| Bodini and colleagues31 (CA) | CD | Prospective cohort study (23) | ADM: trough | 7.5 | 9.5 | p = 0.002 |
| Imaeda and colleagues43 | CD | Prospective cohort study (40) | ADM: trough | 5.5 | 16.0 | – |
| Yarur and colleagues32 (CA) | CD or UC cohort | Prospective cohort study (66) | ADM: timing unknown | 5.7 | 12.5 | – |
| Frederiksen and colleagues (CA)30
Frederiksen and colleagues48 |
CD or UC cohort | Retrospective cohort study (142) | ADM: trough | 0 | 8.3 | p < 0.0001 |
| Schreiber and colleagues44
Sandborn and colleagues27 Lichtenstein and colleagues45 Sandborn and colleagues33 |
CD | RCT (668) | CZP: 26 weeks 40 weeks 56 weeks 72 weeks 80 weeks |
6.1 1.0 0.9 1.5 1.6 |
23.8 9.0 8.7 8.7 9.4 |
– – – – – |
| Stefan and colleagues34 (CA) | CD | RCT and LTE (594) | CZP: trough | 2–4 | 8–12 | – |
a
All values presented to a maximum of one decimal place.
ADAbs, anti-drug antibodies; ADM, adalimumab; CA, conference abstract; CD, Crohn’s disease; conc., concentration; CZP, certolizumab pegol; IFX, infliximab; LTE, long-term extension; NR, not reported; RCT, randomized controlled trial; UC, ulcerative colitis.